StockData
CERo Therapeutics Holdings, Inc. logo

CERo Therapeutics Holdings, Inc. (CERO) stock

CEROOTCBiological Products, (No Diagnostic Substances)Fiscal year ends December 31Also trades as CEROW
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 13, 2026Score 4/30
$0.01+0.00 (0.00%)

Close on Oct 19, 2026Market cap $253.05KP/E –Yield 172833.33%

CERo Therapeutics operating cash flow

Operating cash flow is the cash the business generates from its day-to-day operations.

CERo Therapeutics's operating cash flow for the twelve months ending Dec 31, 2023 was -$1.52M. For fiscal 2025 it was -$16.10M.

Annual operating cash flow

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$16.10M–
FY2023Dec 31, 2023-$1.52M–
FY2022Dec 31, 2022-$1.09M–

Quarterly operating cash flow

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026-$7.89M–
Q1 FY2026Mar 31, 2026$2.80M–
Q4 FY2023Dec 31, 2023-$186.61K–
Q3 FY2023Sep 30, 2023-$256.12K–
Q2 FY2023Jun 30, 2023-$883.10K–
Q1 FY2023Mar 31, 2023-$197.78K–
Q4 FY2022Dec 31, 2022-$373.10K–
Q3 FY2022Sep 30, 2022-$174.35K–
Q2 FY2022Jun 30, 2022-$236.71K–
Q1 FY2022Mar 31, 2022-$308.09K–

More CERo Therapeutics figures

See a number that looks wrong?